ArticleEJHaem2026
Successful Full-Term Pregnancy in Clinically Diagnosed Congenital Thrombotic Thrombocytopenic Purpura: A Case Report and Literature Review.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy resulting from severe ADAMTS13deficiency. Congenital TTP (cTTP, Upshaw-Schulman syndrome) arises from biallelic mutations in the ADAMTS13 gene, leading to lifelong enzyme deficiency, often manifesting in childhood and requiring chronic plasma replacement. Pregnancy physiologically decreases ADAMTS13 activity, predisposing affected women to relapses and adverse outcomes if untreated. Case Presentation: We report a case of a 32-year-old Iranian woman with childhood-onset cTTP managed with long-term fresh frozen plasma (FFP) prophylaxis. After two early miscarriages, her regimen was intensified to FFP every 10 days. During her third pregnancy, ADAMTS13 monitoring was limited, so surrogate markers (platelet count and lactate dehydrogenase) guided therapy. In the third trimester, when ADAMTS13 reached the lower normal limit, FFP was increased to weekly. She delivered a healthy male infant (3200 g, Apgar 8/10) at 37 weeks + 4 days via cesarean section, complicated only by diet-controlled gestational diabetes. Discussion: This case highlights that individualized FFP prophylaxis can enable successful full-term pregnancy in cTTP even in resource-limited settings lacking ADAMTS13 testing. Reliance on clinical and hemolysis markers offers a practical alternative for monitoring. Prophylactic plasma replacement remains essential to prevent relapses and optimize maternal-fetal outcomes in cTTP pregnancies. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.